Palvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 76.7% and free cash flow fell 136.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow PVLA
Palvella Therapeutics, Inc. (PVLA) Piotroski F-score
Palvella Therapeutics, Inc.'s Piotroski F-score for fiscal 2022 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 3 in fiscal 2021.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2022 | 2 | (1.00) |
| FY2021 | 3 | 2.00 |
| FY2020 | 1 | (4.00) |
| FY2019 | 5 | 1.00 |
| FY2018 | 4 | (1.00) |
| FY2017 | 5 | 2.00 |
| FY2016 | 3 | — |
How fiscal 2022’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (26.72%) | (35.38%) | Fail | 0 |
| Positive operating cash flow | (59.93m) | (7.66m) | Fail | 0 |
| Rising return on assets | (26.72%) | (35.38%) | Pass | 1 |
| Cash flow above net income | (26.65m) | 38.08m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 2.01 | 2.52 | Fail | 0 |
| No new shares issued | 927,200 | 806,800 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.21 | 0.24 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ZYME Zymeworks Inc. compare | 7 |
| MESO Mesoblast Limited compare | 5 |
| VIR Vir Biotechnology, Inc. compare | 4 |
| SRPT Sarepta Therapeutics, Inc. compare | 3 |
| XNCR Xencor, Inc. compare | 3 |
| URGN Urogen Pharma compare | 2 |
| PVLA Palvella Therapeutics, Inc. | 2 |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 2 |
| MLYS Mineralys Therapeutics, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover